Literature DB >> 7769587

Two macroprolactinomas presenting with neurological signs.

E G Khan1, T A Howlett.   

Abstract

Macroprolactinomas commonly cause pressure effects on immediate parasellar structures, in particular on the optic chiasm to cause visual field defects. Pressure on more distant brain structures is rarely reported. We describe two massive prolactinomas presenting with neurological signs, including signs of hemiparesis which, to our knowledge, has not been reported previously.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769587      PMCID: PMC1295113     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  7 in total

1.  Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up.

Authors:  S Tsagarakis; A Grossman; P N Plowman; A E Jones; R Touzel; L H Rees; J A Wass; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1991-05       Impact factor: 3.478

Review 2.  Radiation oncogenesis in relation to the treatment of pituitary tumours.

Authors:  A Jones
Journal:  Clin Endocrinol (Oxf)       Date:  1991-11       Impact factor: 3.478

3.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

4.  Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas.

Authors:  M A Faria; G T Tindall
Journal:  J Neurosurg       Date:  1982-01       Impact factor: 5.115

5.  Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.

Authors:  O Serri; E Rasio; H Beauregard; J Hardy; M Somma
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

6.  Bromocriptine in management of large pituitary tumours.

Authors:  J A Wass; J Williams; M Charlesworth; D P Kingsley; A M Halliday; I Doniach; L H Rees; W I McDonald; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

7.  Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.

Authors:  M E Molitch; R L Elton; R E Blackwell; B Caldwell; R J Chang; R Jaffe; G Joplin; R J Robbins; J Tyson; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1985-04       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.